Table 3.

Linkage-to-care and treatment rate of hepatitis C

Index		2018			2019			2020			Averag (2018–2020)
		Total	Male	Female	Total	Male	Female	Total	Male	Female
Estimated anti-HCV positive population, n		290,803	142,138	148,665	273,754	110,628	163,126	327,432	184,348	143,084	297,330
	Anti-HCV positive rate, %	0.56	0.55	0.57	0.53	0.43	0.57	0.63	0.71	0.55	0.57
Estimated HCV RNA positive population, n		86,212	39,244	46,967	87,669	38,264	49,405	102,970	54,461	48,509	92,284
	HCV RNA positive rate	0.30	0.28	0.32	0.32	0.35	0.30	0.31	0.30	0.34	0.31
Linkage-to-care population, n		63,989	31,253	32,736	61,299	29,780	31,519	53,861	26,149	27,712	59,716
	Linkage-to-care rate, %	74.2	79.6	69.7	69.9	77.8	63.8	52.3	48.0	57.1	65.5
Reported CHC cases, n		6,596	3,130	3,466	6,211	3,006	3,205	5,713	2,796	2,917	6,173
	Annual incidence rate, per 100,000 persons	12.7	12.1	13.4	12.0	11.6	12.3	11.0	10.8	11.2	11.9
Treated CHC population, n		3,752	1,722	2,030	3,760	1,756	2,004	3,027	1,430	1,597	3,513
	Treatment rate, %	56.9	55.0	58.6	60.5	58.4	62.5	53.0	51.1	54.7	56.8

CHC, chronic hepatitis C; HCV, hepatitis C virus.